製薬用コクリスタル:設計,製造,応用,課題の検討
Suvarna Jagannath Shelke1, Dhanashri Haushiram Bhangare1, Mayuri Deepak Patil1
1Department of Pharmaceutics, SMBT College Of Pharmacy, Nashik, Maharashtra, India.
まとめ
溶解性や生物利用性などの 薬剤特性を高めます このレビューは,その設計,準備,およびアプリケーションをカバーし,新しい製剤の可能性を提示します.
科学分野:
- 材料科学
- 医薬品科学
- クリスタル・エンジニアリング
背景:
- 製薬用コクリスタルは,活性製薬成分 (API) の物理化学的性質を高める多成分結晶固体である.
- 薬理学的活性を変えることなく,溶解性,生物利用性,安定性,溶解率を改善します.
- コクリスタルは,水素結合や π-π スタッキングなどの非イオン相互作用によって形成されます.
研究 の 目的:
- 薬用コクリスタルの進化,設計,製造,応用について見直す.
- 薬剤の性能を改善し,制御された放出を可能にし,知的財産を創出する可能性を強調します.
- コクリスタルの開発における課題と規制上の検討について議論する.
主な方法:
- 溶剤ベースの (例えば,溶剤の蒸発,冷却結晶化) と固体ベースの (例えば,研磨,液体補助研磨) 方法を含む様々な製剤技術の探索.
- 水素結合傾向と超分子合成アプローチに焦点を当てた設計戦略の議論.
- 分子互換性,熱力学的障壁,規制上の障害などの課題を分析する.
主要な成果:
- 製薬コクリスタルは 薬の配達と製剤の最適化のための 多様なプラットフォームを提供します.
- コクリステル技術の成功は 薬の効能と患者の服従の改善につながります
- 水晶工学の進歩と 規制当局の承認は 商業化への道を開いています
結論:
- 薬用コクリスタルは,薬の開発における重要な進歩であり,強化された物理化学的および薬動学的プロファイルを提供します.
- 既存の課題を克服し,コクリスタル技術の商業的可能性を十分に活用するには,さらなる研究が不可欠です.
- このレビューは,治療上の利点のために薬の投与と配列の最適化におけるコクリステルの有望さを強調しています.
関連する概念動画
Crystal Growth: Principles of Crystallization
5.7K
Crystallization is a phase transformation process in which crystals are precipitated from a supersaturated solution or formed from other sources. During crystallization, atoms or molecules arrange themselves into a well-defined, rigid crystal lattice to minimize energy.
Initiating crystallization involves manipulating the concentration of the solute and the temperature of the solution. Since crystal growth occurs when the ratio of concentration and solubility of the solute in the solvent...
Initiating crystallization involves manipulating the concentration of the solute and the temperature of the solution. Since crystal growth occurs when the ratio of concentration and solubility of the solute in the solvent...
5.7K
Factors Affecting Dissolution: Polymorphism, Amorphism and Pseudopolymorphism
883
Polymorphism refers to the existence of a drug substance in multiple crystalline forms, known as polymorphs. Recently, this term has been expanded to include solvates (forms containing a solvent), amorphous forms (non-crystalline forms), and desolvated solvates (forms from which the solvent has been removed).
Some polymorphic crystals possess lower aqueous solubility than their amorphous counterparts, leading to incomplete absorption. For instance, the oral suspension of Chloramphenicol, which...
Some polymorphic crystals possess lower aqueous solubility than their amorphous counterparts, leading to incomplete absorption. For instance, the oral suspension of Chloramphenicol, which...
883
Factors Affecting Dissolution: Drug Permeability, Stability and Stereochemistry
733
Orally administered drugs primarily enter the systemic circulation via passive diffusion through the intestinal membranes. The drug's absorption is influenced by drug stability in the gastrointestinal GI tract, membrane permeability, the surface area available for absorption, luminal drug concentration, and residence time in the lumen. Drug permeability can be enhanced by adjusting the lipophilicity, polarity, or molecular size of the drug, promoting its passive transport across intestinal...
733
Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
332
Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
332
Biopharmaceutical Factors Influencing Drug Product Design: Overview
547
Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though...
547
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
226
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
226


